Li Ka-Shing’s Horizon Ventures co-leads $40m round in infant probiotic firm Evolve

Evolve BioSystems
Evolve BioSystems' flagship infant probiotic product Evivo. Photo from company website.

Horizon Ventures, the private investment arm of Hong Kong-based billionaire Li Ka-shing, has co-led a $40-million Series C funding round in US-based infant gut microbiome company Evolve BioSystems.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at